Press coverage about Akcea Therapeutics (NASDAQ:AKCA) has trended somewhat negative recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Akcea Therapeutics earned a news sentiment score of -0.05 on Accern’s scale. Accern also gave press coverage about the company an impact score of 47.4625232211477 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- Akcea Therapeutics (AKCA) Upgraded to “Buy” by BidaskClub (americanbankingnews.com)
- Akcea Therapeutics (AKCA) Stock Rating Lowered by Wells Fargo (americanbankingnews.com)
- Akcea Therapeutics (AKCA) Cut to Hold at Stifel Nicolaus (americanbankingnews.com)
- Cowen Lowers Akcea Therapeutics (AKCA) to Market Perform (americanbankingnews.com)
- BMO Capital Markets Boosts Akcea Therapeutics (AKCA) Price Target to $30.00 (americanbankingnews.com)
A number of research firms have recently commented on AKCA. Stifel Nicolaus raised their price objective on shares of Akcea Therapeutics from $20.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, March 16th. Wells Fargo raised shares of Akcea Therapeutics from a “market perform” rating to an “outperform” rating in a report on Thursday, March 15th. BidaskClub raised shares of Akcea Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, March 6th. Zacks Investment Research raised shares of Akcea Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 19th. Finally, Cowen downgraded shares of Akcea Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, February 27th. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $24.75.
TRADEMARK VIOLATION WARNING: This report was first posted by BBNS and is the property of of BBNS. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://baseballnewssource.com/2018/03/29/akcea-therapeutics-akca-receives-coverage-optimism-rating-of-0-05/1971872.html.
Akcea Therapeutics Company Profile
Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).
Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.